(Q43433771)

23 November 2017

1 reference

title

Noninvasive assessment of liver fibrosis in patients with chronic hepatitis virus C (English)

1 reference

23 November 2017

Jérôme Guéchot

1

1 reference

23 November 2017

Groupe de Travail "Marqueurs Biologiques de Fibrose Hépatique"

series ordinal

2

1 reference

23 November 2017

language of work or name

French

0 references

publication date

1 September 2006

1 reference

23 November 2017

1 reference

23 November 2017

volume

35

1 reference

23 November 2017

issue

9 Pt 2

1 reference

23 November 2017

page(s)

1317-1326

1 reference

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

23 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF).

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Sources of variability in histological scoring of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Sampling variability of liver fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Prothrombin index is an indirect marker of severe liver fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Noninvasive diagnosis of hepatic fibrosis or cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Biochemical markers of hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: relationship to liver histology

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Noninvasive markers of fibrosis for longitudinal assessment of fibrosis in chronic liver disease: are they ready for prime time?

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Serum markers detect the presence of liver fibrosis: a cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

A novel panel of blood markers to assess the degree of liver fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases.

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Harmonization of liver enzyme results: calibration for aminotransferases and gamma glutamyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

Analytical variability of the Fibrotest proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0755-4982%2806%2974811-4

7 January 2021

10.1016/S0755-4982(06)74811-4

Identifiers

DOI

1 reference

23 November 2017

1 reference